Skip to main content
Smart Investors Daily
Edwards Lifesciences Corporation logo

NYSE · EW

Edwards Lifesciences Corporation

Healthcare · Medical - Devices

$103.88

Down-$1.35 (-1.28%)

Updated Nov 20, 2026, 2:01 AM

SID Score

7.5/10

Composite research score

Smart Money

58/100

Neutral

Market cap
49.46B
P/E ratio
36.1
Dividend yield
0.00%
52-week range
$74.66 – $108.00
Volume
3.7M
Avg. volume
4.51M

Price performance · EW

EW price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

EW closed at $103.88 after 21 trading sessions, up 15.31% for the selected period.

Last close
$103.88
Period change
+15.31%
Period low
$89.07
Period high
$107.15
Daily close
View OHLC price history
EW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$105.11$105.3425$103.49$103.883.7M
Nov 18, 2026$104.74$106.56$103.0683$105.233.92M
Nov 17, 2026$106.22$107.85$105.12$105.434.27M
Nov 16, 2026$107.00$108.00$104.94$107.114.54M
Nov 13, 2026$106.105$107.69$106.01$107.153.82M
Nov 12, 2026$106.07$106.80$104.93$105.804.18M
Nov 11, 2026$103.76$106.045$102.73$105.814.25M
Nov 10, 2026$104.25$104.585$102.43$104.013.78M
Nov 9, 2026$102.85$105.37$102.17$104.716.68M
Nov 6, 2026$99.00$102.19$98.50$102.145.11M
Nov 5, 2026$100.67$104.165$98.77$100.829.23M
Nov 4, 2026$98.58$100.253$96.72$99.377.9M
Nov 3, 2026$93.67$96.09$93.27$95.196.56M
Nov 2, 2026$93.16$95.75$87.90$93.2612.17M
Oct 30, 2026$94.55$95.34$91.87$92.016.04M
Oct 29, 2026$92.63$95.20$91.995$94.444.68M
Oct 28, 2026$89.98$92.12$89.9001$91.782.3M
Oct 27, 2026$90.19$91.33$89.7301$90.823.02M
Oct 26, 2026$89.07$90.7133$88.91$90.563.33M
Oct 23, 2026$90.11$91.05$88.97$89.073.1M
Oct 22, 2026$88.64$90.19$88.28$90.093.05M

Latest EW news

The latest Smart Investors Daily articles mentioning EW.

EW research

Overview

Company profile and research snapshot.

Company profile

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$95.40
Implied upside
—
Analysts
18
EW recent ratings
DateFirmRatingTarget
Nov 16, 2026Wells FargoOverweight—
Nov 11, 2026TD CowenBuy—
Nov 5, 2026Evercore ISI GroupOutperform—
Nov 5, 2026BTIGBuy—
Nov 5, 2026CitigroupBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 9, 2026

Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment

Market Updates News Commentary - Health care stocks moved higher with the broader market on Monday morning. As of 9:58 a.m. ET, the State Street Health Care Select Sector SPDR ETF was up 0.88% at $186.42, while the S&P 500 was up 1.70% at 7,501.96. Medicare Open Enrollment is underway, and over the past week companies in pharmaceuticals, biotechnology, health insurance, medical devices and drug distribution have reported quarterly results or regulatory news. Active Companies from around the mark

Yahoo · Nov 7, 2026

Edwards Lifesciences Q3 Earnings Call Highlights

Edwards Lifesciences (NYSE:EW) raised its 2026 sales and earnings guidance after third-quarter results exceeded management’s expectations, with growth across its heart-valve businesses and regions. The medical device maker reported sales of $1.72 billion, up 11.2% from a year earlier, and adjusted

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.